{"id":"CHEMBL1141","canonicalSmiles":"[I-].[K+]","inchiKey":"NLKNQRATVPKPDG-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"POTASSIUM IODIDE","yearOfFirstApproval":1979,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Iosat","Jodetten depot","Kaliumjodid","Pot iodide ammoniat","Potassium iodide","Thyro-block","Thyrosafe","Thyroshield"],"synonyms":["Iodine (as potassium iodide)","Iodine (as potassium)","Kali iodatum","Kalii iodidum","NSC-77362","Potassium iodide"],"crossReferences":{"DailyMed":["potassium%20iodide"],"DrugCentral":["4296"],"Wikipedia":["Potassium_iodide"],"drugbank":["DB06715"],"chEBI":["8346"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for anemia (phenotype) and eye disease and has 5 investigational indications."}
{"id":"CHEMBL1173655","canonicalSmiles":"CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1","inchiKey":"ULXXDDBFHOBEHA-CWDCEQMOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AFATINIB","yearOfFirstApproval":2013,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Gilotrif","Giotrif"],"synonyms":["Afatinib","BIBW-2992","BIBW2992","Bibw 2992","NSC-750691","Tomtovok","Tovok"],"crossReferences":{"DailyMed":["afatinib%20dimaleate"],"Wikipedia":["Afatinib"],"drugbank":["DB08916"],"chEBI":["61390"]},"childChemblIds":["CHEMBL2105712"],"linkedTargets":{"rows":["ENSG00000146648","ENSG00000178568","ENSG00000141736"],"count":3},"linkedDiseases":{"rows":["EFO_0003869","EFO_0003859","EFO_0001065","MONDO_0021117","MONDO_0007254","EFO_0000708","HP_0000083","EFO_1001480","Orphanet_178","EFO_0009709","MONDO_0008903","MONDO_0001657","EFO_0000673","EFO_0000326","EFO_0000707","MONDO_0018352","EFO_0000616","EFO_0002618","EFO_0005922","EFO_1001956","EFO_0003060","EFO_0000311","EFO_0003863","EFO_0001421","EFO_0004284","EFO_0000702","EFO_0004142","EFO_0001378","MONDO_0024880","EFO_0000181","EFO_0000519"],"count":31},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 3 approved and 25 investigational indications."}
{"id":"CHEMBL1196088","canonicalSmiles":"NCCc1cnc(S)n1[C@H]1COc2c(F)cc(F)cc2C1","inchiKey":"CWWWTTYMUOYSQA-LLVKDONJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1196088","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB15288"]},"childChemblIds":["CHEMBL555886"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1200457","drugType":"Small molecule","blackBoxWarning":true,"name":"GADOVERSETAMIDE","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Optimark"],"synonyms":["Gadoversetamide","MP-1177"],"crossReferences":{"DrugCentral":["4147"],"Wikipedia":["Gadoversetamide"],"chEBI":["31644"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200607","canonicalSmiles":"FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F","inchiKey":"ZJIJAJXFLBMLCK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PERFLEXANE","yearOfFirstApproval":2002,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["AF-0150","AF0150","Perflexane","Perfluorohexane"],"crossReferences":{"PubChem":["144205881"],"drugbank":["DB09531"],"chEBI":["39427"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2002."}
{"id":"CHEMBL1200618","canonicalSmiles":"CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1.Cl","inchiKey":"RRJFVPUCXDGFJB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FEXOFENADINE HYDROCHLORIDE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL914","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Allegra","Allegra allergy","Allegra hives","Children's allegra allergy","Children's allegra hives","Children's fexofenadine hydrochloride allergy","Children's fexofenadine hydrochloride hives","Fexofenadine hydrochloride","Fexofenadine hydrochloride allergy","Fexofenadine hydrochloride hives","Telfast 120","Telfast 180","Telfast 30"],"synonyms":["Fexofenadine hcl","Fexofenadine hydrochloride","MDL 16,455A","MDL-16455A"],"crossReferences":{"DailyMed":["fexofenadine%20hydrochloride"],"PubChem":["144206676","170464669","26749923","26753303","50085984"]},"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["EFO_0005854","EFO_0005531","EFO_0004253","MONDO_0005271","EFO_1001417","EFO_0003956"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 2 investigational indications."}
{"id":"CHEMBL1200961","canonicalSmiles":"CN(C)CCC(c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\\C(=O)O","inchiKey":"SRGKFVAASLQVBO-BTJKTKAUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BROMPHENIRAMINE MALEATE","yearOfFirstApproval":1957,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL811","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Brompheniramine maleate","Dimegan","Dimetane","Dimetane-ten","Dimotane","Dimotane l.a."],"synonyms":["(+)-Brompheniramine Maleate","Brompheniramine fumarate","Brompheniramine maleate","NSC-758652","Parabromdylamine maleate"],"crossReferences":{"DailyMed":["brompheniramine%20maleate"],"PubChem":["26747454","50105943","56422493","855910","93576630"],"chEBI":["3184"]},"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["EFO_0008521","MP_0001845","HP_0012735","MONDO_0005271","EFO_0007214"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 3 approved indications."}
{"id":"CHEMBL1200967","canonicalSmiles":"CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1.Cl","inchiKey":"ZQDJSWUEGOYDGT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BROMODIPHENHYDRAMINE HYDROCHLORIDE","yearOfFirstApproval":1954,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201245","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ambodryl"],"synonyms":["Bromazine","Bromodiphenhydramine hcl","Bromodiphenhydramine hydrochloride","NSC-36113"],"crossReferences":{"chEBI":["59178"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954."}
{"id":"CHEMBL1201022","canonicalSmiles":"Cl.Nc1ccc(/N=N/c2ccccc2)c(N)n1","inchiKey":"QQBPIHBUCMDKFG-GEEYTBSJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENAZOPYRIDINE HYDROCHLORIDE","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1242","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Pyridium","Uropyrine"],"synonyms":["NC 150","NC-150","NSC-1879","Phenazopyridine hcl","Phenazopyridine hydrochloride","W 1655","W-1655"],"crossReferences":{"PubChem":["17389769","26748196","26752976"]},"linkedTargets":{"rows":["ENSG00000153253","ENSG00000185313","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000007314","ENSG00000136531","ENSG00000196876"],"count":10},"linkedDiseases":{"rows":["EFO_0003103","EFO_0003901"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and has 1 investigational indication."}
{"id":"CHEMBL1201084","canonicalSmiles":"[131I-].[Na+]","inchiKey":"FVAUCKIRQBBSSJ-LAIFMVDKSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"SODIUM IODIDE I 131","maximumClinicalTrialPhase":4,"parentId":"CHEMBL1644695","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Hicon","Iodotope","Iodotope i-131","Iodotope therapeutic","Oriodide","Radiocaps-131","Sodium Iodide (131I)","Sodium iodide i 131","Theriodide","Tracervial-131"],"synonyms":["Iodine (131i) sodium","Radiocaps","Sodium iodide (131 i)","Sodium iodide (131i)","Sodium iodide (131i) capsules","Sodium iodide i 131","Sodium iodide i-131","Sodium iodide i131","Sodium iodide, i-131","Sodium iodide,i-131","Sodium iodide-131","Theriodide-131","Tracervial"],"crossReferences":{"DailyMed":["sodium%20iodide%20i-131"],"DrugCentral":["5038"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved indications."}
{"id":"CHEMBL1201239","canonicalSmiles":"CC(=O)NCc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I","inchiKey":"VVDGWALACJEJKG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IODAMIDE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Jodomiron","Uromiro","Uromiron"],"synonyms":["B-4130","Iodamide","SH 926","SH-926"],"crossReferences":{"PubChem":["144204899","170465213","26748392"],"Wikipedia":["Iodamide"],"drugbank":["DB08948"],"chEBI":["31703"]},"childChemblIds":["CHEMBL1201172"],"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL1201293","canonicalSmiles":"CC(=O)NCCCS(=O)(=O)O","inchiKey":"AFCGFAGUEYAMAO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACAMPROSATE","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Acamprosate"],"crossReferences":{"DailyMed":["acamprosate%20calcium"],"PubChem":["50112716"],"Wikipedia":["Acamprosate"],"drugbank":["DB00659"],"chEBI":["51041"]},"childChemblIds":["CHEMBL2068724"],"linkedTargets":{"rows":["ENSG00000183454","ENSG00000273079","ENSG00000116032","ENSG00000109158","ENSG00000145863","ENSG00000011677","ENSG00000187730","ENSG00000151834","ENSG00000145864","ENSG00000198785","ENSG00000166206","ENSG00000182256","ENSG00000102287","ENSG00000161509","ENSG00000022355","ENSG00000105464","ENSG00000094755","ENSG00000268089","ENSG00000163285","ENSG00000113327","ENSG00000176884","ENSG00000186297","ENSG00000163288"],"count":23},"linkedDiseases":{"rows":["EFO_0003756","EFO_0005203","HP_0000360","MONDO_0005090","EFO_0002610","MONDO_0002009","HP_0000726","EFO_0003758","EFO_1001917","Orphanet_908","MONDO_0002046","EFO_1001892","EFO_0000289","MONDO_0002050","MONDO_0021698","EFO_0004699","EFO_0004701","MONDO_0007079","EFO_0005230","EFO_0005411"],"count":20},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for alcohol dependence and has 11 investigational indications."}
{"id":"CHEMBL1201664","drugType":"Protein","blackBoxWarning":false,"name":"INSULIN ASPART PROTAMINE RECOMBINANT","yearOfFirstApproval":2001,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Insulin aspart protamine recombinant"],"crossReferences":{"DailyMed":["insulin%20aspart%20protamine%20recombinant"]},"linkedTargets":{"rows":["ENSG00000171105"],"count":1},"linkedDiseases":{"rows":["MONDO_0005148"],"count":1},"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 2001."}
{"id":"CHEMBL1201824","drugType":"Enzyme","blackBoxWarning":true,"name":"ALGLUCOSIDASE ALFA","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Lumizyme","Myozyme"],"synonyms":[".alpha.-glucosidase","Acid .alpha.-glucosidase","Alglucosidase","Alglucosidase alfa","Alglucosidase alfa (genetical recombination)","Alpha-glucopyranosidase","Alpha-glucosidase","GZ419829","Glucosidase, alpha-","Lumizyme","Ndi 709","RHGAA","Transglucosidase"],"crossReferences":{"DailyMed":["alglucosidase%20alfa"],"DrugCentral":["5030"]},"description":"Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for glycogen storage disease due to acid maltase deficiency and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1207745","canonicalSmiles":"CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2c3cccc(CCCC(=O)O)c3O[C@H]2C[C@H]1O","inchiKey":"CTPOHARTNNSRSR-APJZLKAGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BERAPROST","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Beraprost","MDL-201229","ML-1229","TRK-100STP FREE ACID"],"childChemblIds":["CHEMBL435883"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1232205","canonicalSmiles":"Nc1nc2c(ncn2[C@H]2C[C@H](O)[C@@H](CO[P@](=O)(O)OP(=O)(O)O)O2)c(=O)[nH]1","inchiKey":"CIKGWCTVFSRMJU-KVQBGUIXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1232205","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03491"],"chEBI":["28862"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1234168","canonicalSmiles":"C[N+](C)(C)CCCC[C@H](N)C(=O)O","inchiKey":"MXNRLFUSFKVQSK-QMMMGPOBSA-O","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIMETHYLLYSINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Trimethyllysine"],"crossReferences":{"drugbank":["DB03977"],"chEBI":["17311"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1236682","canonicalSmiles":"COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1","inchiKey":"RDSACQWTXKSHJT-NSHDSACASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"REFAMETINIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BAY 869766","BAY 8697661","BAY-86-9766","BAY-869766","BAY-8697661","BAY86-9766","Bay-86-9766","RDEA 119","RDEA-119","Rdea119","Refametinib"],"crossReferences":{"drugbank":["DB06309"]},"linkedTargets":{"rows":["ENSG00000126934","ENSG00000169032"],"count":2},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0003060","EFO_0000182","EFO_0000311"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL123678","canonicalSmiles":"CCOc1cc2ncnc(Nc3cccc(-c4csc(CO)n4)c3)c2cc1OCC","inchiKey":"ZJESXGUODSBHSK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL123678","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02848"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1237066","canonicalSmiles":"O=C([O-])C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]","inchiKey":"FATUQANACHZLRT-KMRXSBRUSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"CALCIUM GLUCEPTATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Calcium gluceptate"],"synonyms":["Calcium gluceptate","Calcium glucoheptonate","Calcium glucoheptonate (1:2)","Calcium glucoheptone","NSC-755885"],"crossReferences":{"DrugCentral":["4433"],"drugbank":["DB00326"],"chEBI":["3314"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL12948","canonicalSmiles":"CC1CCC(NC(=O)N(CCCl)N=O)CC1","inchiKey":"FVLVBPDQNARYJU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SEMUSTINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ICIG 1110","ICIG-1110","METHYL-CCNU","Methyl lomustine","NSC-758471","Semustine"],"crossReferences":{"PubChem":["144204957","26748800","46500621"],"chEBI":["6863"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1349","canonicalSmiles":"CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21","inchiKey":"HDOVUKNUBWVHOX-QMMMGPOBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VALACYCLOVIR","yearOfFirstApproval":1995,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Valtrex","Zelitrex"],"synonyms":["Valaciclovir","Valacv","Valacyclovir"],"crossReferences":{"DailyMed":["valacyclovir%20hydrochloride"],"PubChem":["29215498","56422581"],"Wikipedia":["Valaciclovir"],"drugbank":["DB00577"],"chEBI":["35854"]},"childChemblIds":["CHEMBL1201110"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 28 investigational indications."}
{"id":"CHEMBL1377","canonicalSmiles":"CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1","inchiKey":"SSOLNOMRVKKSON-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHLOROGUANIDE","yearOfFirstApproval":2000,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Chlorguanide","Chloroguanide","Proguanil"],"crossReferences":{"DailyMed":["proguanil%20hydrochloride"],"PubChem":["11112433","174006624"],"Wikipedia":["Proguanil"],"drugbank":["DB01131"],"chEBI":["8455"]},"childChemblIds":["CHEMBL1201059"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for malaria and has 3 investigational indications."}
{"id":"CHEMBL1429","canonicalSmiles":"N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O","inchiKey":"NFLWUMRGJYTJIN-PNIOQBSNSA-N","drugType":"Protein","blackBoxWarning":true,"name":"DESMOPRESSIN","yearOfFirstApproval":1978,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Desmopressin","H01BA02"],"crossReferences":{"DailyMed":["desmopressin%20acetate"],"drugbank":["DB00035"],"chEBI":["4450"]},"childChemblIds":["CHEMBL1200556"],"linkedTargets":{"rows":["ENSG00000126895","ENSG00000166148","ENSG00000198049"],"count":3},"linkedDiseases":{"rows":["EFO_0003086","EFO_0009505","MONDO_0024290","MONDO_0007254","EFO_0005669","EFO_0007344","HP_0001742","EFO_1002048","MONDO_0008315","EFO_0000537","EFO_1001412","MP_0001914","HP_0031364","HP_0002045","HP_0001871","MONDO_0004782","MONDO_0005180","MONDO_0024574","HP_0000863","EFO_1000781","Orphanet_98878","HP_0000103"],"count":22},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 10 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL15413","canonicalSmiles":"CO[C@@]1(NC(=O)CSC(F)F)C(=O)N2C(C(=O)O)=C(CSc3nnnn3CCO)CO[C@@H]21","inchiKey":"UHRBTBZOWWGKMK-DOMZBBRYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLOMOXEF","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Flomoxef","Flomoxef sodium"],"crossReferences":{"Wikipedia":["Flomoxef"],"drugbank":["DB11935"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL157138","canonicalSmiles":"CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1","inchiKey":"BKRGVLQUQGGVSM-KBXCAEBGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LISURIDE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Revanil 200"],"synonyms":["Lisuride","Lisuride maleate","Lysuride","Lysuride maleate"],"crossReferences":{"Wikipedia":["Lisuride"],"drugbank":["DB00589"],"chEBI":["51164"]},"childChemblIds":["CHEMBL1257128"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for migraine disorder and has 3 investigational indications."}
{"id":"CHEMBL16332","canonicalSmiles":"C[C@H](CS)C(=O)N1C[C@@H](Sc2ccccc2)C[C@H]1C(=O)O","inchiKey":"UQWLOWFDKAFKAP-WXHSDQCUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZOFENOPRILAT","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Zofenoprilat"],"crossReferences":{"Wikipedia":["Zofenoprilat"],"drugbank":["DB08766"],"chEBI":["82602"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1743040","drugType":"Antibody","blackBoxWarning":false,"name":"MILATUZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["HLL1","IMMU-115","Milatuzumab"],"linkedTargets":{"rows":["ENSG00000019582"],"count":1},"linkedDiseases":{"rows":["EFO_0000095","EFO_0000574","EFO_0001378","EFO_0006738"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1743073","drugType":"Protein","blackBoxWarning":false,"name":"SOTATERCEPT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ACE-001","ACE-011","ACE011","Sotatercept"],"linkedTargets":{"rows":["ENSG00000122641"],"count":1},"linkedDiseases":{"rows":["EFO_0001361","MONDO_0044903","Orphanet_231222","EFO_0004272","EFO_0001378","Orphanet_231214","EFO_1000388","HP_0012410"],"count":8},"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL178657","canonicalSmiles":"CCN(CC)S(=O)(=O)c1cc(C(=O)Nc2ccccc2C(=O)O)ccc1Br","inchiKey":"VNOMZKMKBNFCMC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL178657","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07429"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1790180","canonicalSmiles":"CC[C@H](C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H]([C@@H](C)O)C(=O)N[C@H]2CSSC[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CCc3ccc(O)cc3)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@@H](Cc3ccccc3)NC2=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N1)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)[C@@H](C)CC","inchiKey":"ZGOVYTPSWMLYOF-QEADGSHQSA-N","drugType":"Protein","blackBoxWarning":false,"name":"ENDOTHELIN 3","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Endothelin 3"],"description":"Protein drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1946618","canonicalSmiles":"CN(CCO)C(=O)c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2cccc3cccnc23)cc1","inchiKey":"ZJKUETLEJYCOBO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD-7268","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZ-12488024","AZ12488024","AZD7268","Azd 7268","Azd-7268","Azd7268"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2035874","canonicalSmiles":"CC(C)c1cc(Oc2c(Br)cc(NC(=O)CC(=O)O)cc2Br)ccc1O","inchiKey":"VPCSYAVXDAUHLT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EPROTIROME","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bms-356384","Eprotirome","Kb-2115","Kb2115"],"crossReferences":{"drugbank":["DB05035"]},"linkedTargets":{"rows":["ENSG00000151090"],"count":1},"linkedDiseases":{"rows":["HP_0003124","EFO_0004911","Orphanet_309005"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2042122","canonicalSmiles":"CNc1ccc(-c2nc3ccc(O)cc3s2)cc1[18F]","inchiKey":"VVECGOCJFKTUAX-HUYCHCPVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUTEMETAMOL F 18","yearOfFirstApproval":2013,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL579205","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vizamyl"],"synonyms":["(18F)AH110690","(18f)flutemetamol","Flutemetamol ((sup18)f)","Flutemetamol (18f)","Flutemetamol F18","Flutemetamol f 18","Flutemetamol f-18","[18F]-Flutemetamol F18","[18F]AH110690"],"crossReferences":{"DailyMed":["flutemetamol%20f-18"],"drugbank":["DB09151"],"chEBI":["76611"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for cognitive impairment and alzheimer disease."}
{"id":"CHEMBL204543","canonicalSmiles":"Oc1ccc2ccccc2c1O","inchiKey":"NXPPAOGUKPJVDI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Naphthalene-1,2-Diol","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Naphthalene-1,2-Diol"],"crossReferences":{"drugbank":["DB07610"],"chEBI":["17435"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2103844","canonicalSmiles":"NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O.O=C(O)/C=C\\C(=O)O.O=C(O)/C=C\\C(=O)O","inchiKey":"SVAGFBGXEWPNJC-SPIKMXEPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIXANTRONE DIMALEATE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL167731","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BBR 2778","BBR 2778 DIMALEATE","BBR-2778 DIMALEATE","NSC-752341","Pixantrone dimaleate","Pixantrone dimaleate salt","Pixantrone maleate","Pixuvri"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2104404","canonicalSmiles":"CC(C)C[C@H]1C(=O)O[C@H](Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N1C","inchiKey":"ZMQMTKVVAMWKNY-YSXLEBCMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EMODEPSIDE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BAY 44-4400","BAY-44-4400","Emodepside","PF 1022-221","PF-1022-221"],"crossReferences":{"drugbank":["DB11403"],"chEBI":["78739"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2104519","canonicalSmiles":"Cc1cc(O)c(C2CC3CCC2(C)C3(C)C)cc1C","inchiKey":"RNRHMQWZFJXKLZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"XIBORNOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["6-isobornyl-3,4-xylenol","Xibornol"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2105711","canonicalSmiles":"CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1.O","inchiKey":"ZXOCGDDVNPDRIW-NHFZGCSJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TOFOGLIFLOZIN","maximumClinicalTrialPhase":3,"parentId":"CHEMBL2110731","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CSG 452","CSG-452","CSG452","R-7201","RO-4998452","RO4998452","Tofogliflozin","Tofogliflozin hydrate","Tofogliflozin monohydrate"],"crossReferences":{"Wikipedia":["Tofogliflozin"]},"linkedTargets":{"rows":["ENSG00000140675"],"count":1},"linkedDiseases":{"rows":["EFO_0003095","MONDO_0005148"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2107373","canonicalSmiles":"Cc1nc2c(N)nc3cccnc3c2n1CC(C)C","inchiKey":"ZXBCLVSLRUWISJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SOTIRIMOD","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["R-850","S-30594","Sotirimod"],"crossReferences":{"drugbank":["DB05680"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2107781","canonicalSmiles":"O=C([O-])[C@H](O)[C@@H](O)C(=O)[O-].[Na+].[Na+]","inchiKey":"HELHAJAZNSDZJO-OLXYHTOASA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"SODIUM TARTRATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Sodium tartrate"],"crossReferences":{"DrugCentral":["4780"],"drugbank":["DB13707"],"chEBI":["63017"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2108061","drugType":"Antibody","blackBoxWarning":false,"name":"VOLOCIXIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["M-200","M200","Volociximab"],"linkedTargets":{"rows":["ENSG00000150093","ENSG00000161638"],"count":2},"linkedDiseases":{"rows":["EFO_0002618","EFO_0001365","EFO_1001100","MONDO_0015686","EFO_0000756","MONDO_0008170","EFO_0000681","MONDO_0008903","EFO_0003060"],"count":9},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL2108688","drugType":"Unknown","blackBoxWarning":false,"name":"SMALLPOX VACCINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Smallpox vaccine"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2109193","drugType":"Antibody","blackBoxWarning":false,"name":"GAVILIMOMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ABX-CBL","Gavilimomab"],"linkedTargets":{"rows":["ENSG00000172270"],"count":1},"linkedDiseases":{"rows":["MONDO_0013730"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2109219","drugType":"Unknown","blackBoxWarning":false,"name":"PERTUSSIS VACCINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Adsorbed purified pertussis vaccine","Bordetella pertussis","Haemophilus pertussis whole","Hemophilus pertussis whole","Microbe de la coqueluche whole","Pertussis vaccine","Pertussis, purified antigen"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL2109328","drugType":"Antibody","blackBoxWarning":false,"name":"IMC-EB10","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["IMC-EB10","Imc-eb10"],"linkedTargets":{"rows":["ENSG00000122025"],"count":1},"linkedDiseases":{"rows":["MONDO_0004643"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109338","drugType":"Antibody","blackBoxWarning":false,"name":"AMG-729","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG-729"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2109374","drugType":"Antibody","blackBoxWarning":false,"name":"TRC-093","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MT-293","TRC-093","TRC093","Trc-093"],"linkedTargets":{"rows":["ENSG00000081052"],"count":1},"linkedDiseases":{"rows":["EFO_0000311","EFO_0009708"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2109539","drugType":"Antibody","blackBoxWarning":false,"name":"RG-7652","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["RG-7652"],"description":"Antibody drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2109636","drugType":"Antibody","blackBoxWarning":false,"name":"VILOBELIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CACP 29","CACP29","Cacp29","IFX-1","Vilobelimab"],"linkedTargets":{"rows":["ENSG00000106804"],"count":1},"linkedDiseases":{"rows":["HP_0100806","MP_0001845","MONDO_0100096","EFO_1000710","EFO_0006834","EFO_0005297","HP_0000999","EFO_0000717","EFO_1000784"],"count":9},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL2110659","canonicalSmiles":"O=C1Cc2c(ccc3c2O[C@@H](CNCc2ccccc2)CO3)N1","inchiKey":"DYJIKHYBKVODAC-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"APLINDORE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aplindore"],"crossReferences":{"drugbank":["DB06620"]},"childChemblIds":["CHEMBL2104864"],"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["MONDO_0005180","EFO_0004270"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL214393","canonicalSmiles":"O=c1ccn([C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1","inchiKey":"DJJCXFVJDGTHFX-XVFCMESISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"UMP","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["UMP","Uridine-5'-Monophosphate"],"crossReferences":{"PubChem":["26756680"],"drugbank":["DB03685"],"chEBI":["16695"]},"childChemblIds":["CHEMBL1627073"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2178422","canonicalSmiles":"N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F","inchiKey":"KRNAOFGYEFKHPB-ANJVHQHFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIMEGEPANT","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["BMS-927711","Bhv-3000","Rimegepant"],"crossReferences":{"DailyMed":["rimegepant%20sulfate"],"drugbank":["DB12457"]},"childChemblIds":["CHEMBL2364629"],"linkedTargets":{"rows":["ENSG00000064989"],"count":1},"linkedDiseases":{"rows":["MONDO_0005277","EFO_1001219","EFO_0007486","EFO_0000676","EFO_0005279","EFO_0003843"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for migraine disorder and has 3 investigational indications."}
{"id":"CHEMBL2180408","canonicalSmiles":"COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1","inchiKey":"BPLVDYJDAVYLRQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-42396302","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Jnj-42396302"],"crossReferences":{"drugbank":["DB12657"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2218913","canonicalSmiles":"C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@H](C2CCNC(=N)N2)NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC1=O.N=C1NCCC([C@@H]2NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC2=O)N1.O=S(=O)(O)O.O=S(=O)(O)O","inchiKey":"TUATYNXRYJTQTQ-BVRBKCERSA-N","drugType":"Protein","blackBoxWarning":true,"name":"CAPREOMYCIN SULFATE","yearOfFirstApproval":1971,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL2221250","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Capastat sulfate"],"synonyms":["34977","Capastat sulphate","Capreomycin disulfate","Capreomycin sulfate","Capreomycin sulphate","Capreomycin, sulfate (salt)","Capreomycini sulfas","NSC-755904","Ogostal"],"crossReferences":{"DailyMed":["capreomycin%20sulfate"]},"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1971 and is indicated for tuberculosis. This drug has a black box warning from the FDA."}
{"id":"CHEMBL223360","canonicalSmiles":"Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1","inchiKey":"MPVGZUGXCQEXTM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LINIFANIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["A-741439","ABT-869","AL-39324","Linifanib","RG-3635"],"crossReferences":{"PubChem":["103904340","137275904","50100086"]},"linkedTargets":{"rows":["ENSG00000134853","ENSG00000128052","ENSG00000102755","ENSG00000037280","ENSG00000113721","ENSG00000182578","ENSG00000122025"],"count":7},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000365","EFO_0001365","EFO_0001065","EFO_0000681","EFO_0000182","MONDO_0007254","EFO_1000657","MONDO_0021063","EFO_0003060"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."}
{"id":"CHEMBL2303617","canonicalSmiles":"C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1.O.O.O.O.O.O=S(=O)(O)O","inchiKey":"WNSDDGBLIALDPB-HTZKOJAYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SPARTEINE SULFATE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL412873","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"]},"tradeNames":[],"synonyms":["NSC-755834","Sparteine Sulfate","Sparteine sulfate","Sparteine sulfate pentahydrate","Sparteine sulphate","Sparteinum sulphuricum"],"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in United States."}
{"id":"CHEMBL232148","canonicalSmiles":"NS(=O)(=O)c1ccc(-c2ccc(/C=C3\\SC(=O)NC3=O)o2)cc1","inchiKey":"JNPRTUHVCHGFHJ-GHXNOFRVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL232148","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["50085448"],"drugbank":["DB07531"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2361370","canonicalSmiles":"CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1.CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1.O=S(=O)(O)O","inchiKey":"FEDSNBHHWZEYTP-ZFQYHYQMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PENBUTOLOL SULFATE","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1290","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Betapressin","Levatol"],"synonyms":["HOE 39-893D","HOE 893D","HOE-39-893D","HOE-893D","NSC-760043","Penbutolol sulfate","Penbutolol sulphate"],"crossReferences":{"PubChem":["144204192"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987."}
{"id":"CHEMBL23838","canonicalSmiles":"CCOP(=O)(OCC)Oc1ccc([N+](=O)[O-])cc1","inchiKey":"WYMSBXTXOHUIGT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PARAOXON","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Diethyl p-nitrophenyl phosphate","E-600","Miotisal","NSC-404110","Paraoxon","Parathion oxygen analog","Phosphacol"],"crossReferences":{"PubChem":["144209622","144213364","26757694"],"Wikipedia":["Paraoxon"],"drugbank":["DB13495"],"chEBI":["27827"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL242948","canonicalSmiles":"NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)O","inchiKey":"CQOVPNPJLQNMDC-ZETCQYMHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"POLAPREZINC","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Carnosine","Polaprezinc","Z 103","Z-103"],"crossReferences":{"PubChem":["11113307","26754272"],"Wikipedia":["Carnosine"],"drugbank":["DB11695"],"chEBI":["15727"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL245549","canonicalSmiles":"Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1Nc1ncccc1-c1ccncn1","inchiKey":"NESXBRNDMQUVNG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL245549","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08221"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL300138","canonicalSmiles":"Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21","inchiKey":"AXRCEOKUDYDWLF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ENZASTAURIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Kinenza"],"synonyms":["DB-102","DB102","Enzastaurin","LY-317615","LY317615","Ly-317615"],"crossReferences":{"PubChem":["137275839","144206918","170465609"],"Wikipedia":["Enzastaurin"],"drugbank":["DB06486"]},"childChemblIds":["CHEMBL2107337"],"linkedTargets":{"rows":["ENSG00000166501"],"count":1},"linkedDiseases":{"rows":["EFO_0003869","EFO_0000365","MONDO_0100342","EFO_0000681","EFO_0002913","EFO_1001465","MONDO_0007254","EFO_1001469","EFO_0005952","MONDO_0002087","EFO_1001951","EFO_0000096","EFO_0003860","MONDO_0008903","EFO_0004289","EFO_1000251","EFO_0000326","EFO_0004288","EFO_1000158","EFO_0009441","EFO_0000616","MONDO_0008170","EFO_0000403","EFO_0003060","MONDO_0008315","EFO_0000621","EFO_0000311","EFO_1001100","EFO_0000702","EFO_0000574","EFO_0001378","MONDO_0018906","EFO_0000519"],"count":33},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 34 investigational indications."}
{"id":"CHEMBL3039544","drugType":"Protein","blackBoxWarning":false,"name":"TECEMOTIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Stimuvax"],"synonyms":["BLP-25","BLP25","BP-1-148","Blp 25","Blp-25 lipopeptide","EMD 531444","Emepepimut-s","LIPOPEPTIDE BLP-25","Tecemotide"],"linkedTargets":{"rows":["ENSG00000185499"],"count":1},"linkedDiseases":{"rows":["MONDO_0008903","EFO_1000657","MONDO_0007254","EFO_0001378","EFO_1001950","EFO_0003060","MONDO_0044937","MONDO_0008315"],"count":8},"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL305380","canonicalSmiles":"Cc1ccc(Cl)c(OCC(O)CNC(C)(C)C)c1","inchiKey":"HQIRNZOQPUAHHV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BUPRANOLOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["B 1312 [AS HYDROCHLORIDE]","Bupranol","Bupranolol","Bupranolol hydrochloride","KL-255 [AS HYDROCHLORIDE]","Ophtorenin"],"crossReferences":{"PubChem":["170465802"],"Wikipedia":["Bupranolol"],"drugbank":["DB08808"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3187365","canonicalSmiles":"CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1","inchiKey":"VSWBSWWIRNCQIJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ASENAPINE","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Secuado","Sycrest"],"synonyms":["Asenapine"],"crossReferences":{"DailyMed":["asenapine","asenapine%20maleate"],"PubChem":["124899263"],"chEBI":["71255"]},"childChemblIds":["CHEMBL3544974"],"linkedTargets":{"rows":["ENSG00000149295","ENSG00000102468"],"count":2},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0000289","MONDO_0002009","EFO_0000677","EFO_0009963","EFO_0005407","EFO_0001358","EFO_0005411","HP_0000713"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 4 approved and 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3301576","drugType":"Unknown","blackBoxWarning":false,"name":"PEGPLERANIB SODIUM","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Fovista"],"synonyms":["E-01AJ","E-10030","E01AJ","E10030","Pegpleranib sodium","X-01E","X01E"],"linkedTargets":{"rows":["ENSG00000100311"],"count":1},"linkedDiseases":{"rows":["Orphanet_892","EFO_0001365"],"count":2},"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3301599","canonicalSmiles":"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O.C[C@H](O)C(=O)O","inchiKey":"VYRWEWHOAMGLLW-WNQIDUERSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ONALESPIB LACTATE","maximumClinicalTrialPhase":1,"parentId":"CHEMBL1214827","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AT-13387 LACTATE","ATI-13387A","ATI-13387AU","ATI13387A","ATI13387AU","Onalespib l-lactate","Onalespib lactate"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3301672","canonicalSmiles":"CCCCCC/C=C\\CCCCCCCCCC(=O)N[C@H]1[C@H](OC[C@H]2O[C@H](OP(=O)([O-])[O-])[C@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OCCCCCCCCCC)[C@@H]2O)O[C@H](COC)[C@@H](OP(=O)([O-])[O-])[C@@H]1OCC[C@@H](CCCCCCC)OC.[Na+].[Na+].[Na+].[Na+]","inchiKey":"FEMINZOAAWPBPP-RHMAUSBNSA-J","drugType":"Small molecule","blackBoxWarning":false,"name":"ERITORAN TETRASODIUM","maximumClinicalTrialPhase":3,"parentId":"CHEMBL501259","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["B-1287","B1287","E-5564","E5564","Eritoran sodium","Eritoran tetrasodium","Eritoran tetrasodium salt"],"crossReferences":{"chEBI":["46692"]},"linkedTargets":{"rows":["ENSG00000154589","ENSG00000136869"],"count":2},"linkedDiseases":{"rows":["EFO_0000565","HP_0100806"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3348963","canonicalSmiles":"CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1.O=C(O)CNC(=O)c1ccccc1","inchiKey":"XSFPZBUIBYMVEA-CELUQASASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TELOTRISTAT ETIPRATE","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL2105695","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Xermelo"],"synonyms":["LX1032 HIPPURATE","LX1606 HIPPURATE","Telotristat ethyl hippurate","Telotristat etiprate"],"crossReferences":{"DailyMed":["telotristat%20etiprate"]},"linkedTargets":{"rows":["ENSG00000139287","ENSG00000129167"],"count":2},"linkedDiseases":{"rows":["HP_0002014"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for diarrhea."}
{"id":"CHEMBL350320","canonicalSmiles":"NC(=O)[C@@H](N)Cc1ccccc1","inchiKey":"OBSIQMZKFXFYLV-QMMMGPOBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENYLALANINE AMIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04029"],"chEBI":["21371"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3544907","drugType":"Small molecule","blackBoxWarning":false,"name":"PICOPLATIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMD-473","AMD473","NX 473","NX-473","Picoplatin","ZD-0473","ZD0473"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."}
{"id":"CHEMBL3544971","canonicalSmiles":"C[C@H](N)Cc1ccccc1.C[C@H](N)Cc1ccccc1.O=S(=O)(O)O","inchiKey":"PYHRZPFZZDCOPH-QXGOIDDHSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"DEXTROAMPHETAMINE SULFATE","yearOfFirstApproval":1960,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL612","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dexampex","Dexedrine","Dextroamphetamine sulfate","Dextrostat","Ferndex"],"synonyms":["Amphetamine sulfate, dextro","D-amphetamine hemisulfate salt","Dexamfetamine sulfate","Dexamphetamine sulfate","Dexamphetamine sulphate","Dextroamphetamine sulfate","Dextroamphetamine sulfate cii","Dextroamphetamine sulphate","NSC-27104"],"crossReferences":{"DailyMed":["dextroamphetamine%20sulfate"],"chEBI":["51064"]},"linkedTargets":{"rows":["ENSG00000103546","ENSG00000142319","ENSG00000165646"],"count":3},"linkedDiseases":{"rows":["EFO_0003888","MONDO_0016158"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for attention deficit hyperactivity disorder and narcolepsy-cataplexy syndrome. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3545236","drugType":"Small molecule","blackBoxWarning":false,"name":"BPI-9016","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BPI-9016M","Bpi-9016"],"linkedTargets":{"rows":["ENSG00000167601","ENSG00000105976"],"count":2},"linkedDiseases":{"rows":["EFO_0000616","EFO_0003060"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3695568","canonicalSmiles":"COCC(=O)Nc1cc(COc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)c3ccccc23)ccn1","inchiKey":"RTDCVLCTBQDLBW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-49095397","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["JNJ-49095397","Jnj-49095397","RV-568","RV568","Rv568"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3707275","drugType":"Gene","blackBoxWarning":false,"name":"VORETIGENE NEPARVOVEC","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AAV-2-HRPE65V2","AAV2-hRPE65v2","Luxturna","SPK-RPE65","Voretigene neparvovec","Voretigene neparvovec-rzyl"],"linkedTargets":{"rows":["ENSG00000116745"],"count":1},"linkedDiseases":{"rows":["EFO_0003966","Orphanet_71862","Orphanet_65"],"count":3},"description":"Gene drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL372227","canonicalSmiles":"O=C(O)c1sccc1S(=O)(=O)Nc1ccc(Cl)cc1","inchiKey":"YRWKEEDITQJPCZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL372227","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08573"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL373081","canonicalSmiles":"CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1","inchiKey":"DNYGXMICFMACRA-XHEDQWPISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MICRONOMICIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["6'-n-methylgentamicin c1a","Gentamicin c2b","Micronomicin","Micronomicin sulfate"],"crossReferences":{"drugbank":["DB13274"],"chEBI":["81283"]},"childChemblIds":["CHEMBL515234"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL375530","canonicalSmiles":"OC[C@H]1O[C@@H](n2cnc3cc(Cl)c(Cl)cc32)[C@H](O)[C@@H]1O","inchiKey":"XHSQDZXAVJRBMX-DDHJBXDOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DICHLORORIBOBENZIMIDAZOLE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["5,6-Dichlorobenzimidazole Riboside","Dichlororibobenzimidazole"],"crossReferences":{"PubChem":["56463021"],"Wikipedia":["5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole"],"drugbank":["DB08473"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3952064","canonicalSmiles":"C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2nc(NC(=O)c3ccc(OC(F)F)cn3)cs2)CO1","inchiKey":"ZLZUHACSRMOLLV-RAALSFIWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3952064","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB15105"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL402823","canonicalSmiles":"N#Cc1cc(Cl)cc(Oc2cc(OCc3n[nH]c4ccccc34)ccc2Cl)c1","inchiKey":"WHCLIFOVZDANCU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL402823","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08154"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4073443","canonicalSmiles":"Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1","inchiKey":"HKTBYUWLRDZAJK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TOMIVOSERTIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["EFT-508","Eft 508","Eft508","Tomivosertib","eFT508"],"crossReferences":{"drugbank":["DB15219"]},"childChemblIds":["CHEMBL4298140"],"linkedTargets":{"rows":["ENSG00000099875","ENSG00000079277"],"count":2},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0007254","EFO_0000574","EFO_0003060","MONDO_0008315","EFO_1001951","EFO_0000311"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL412309","canonicalSmiles":"CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccc(O)cc1c2[Si](C)(C)C(C)(C)C","inchiKey":"XUSKJHCMMWAAHV-SANMLTNESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AR-67","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AR67","Ar-67","DB 67","DB-67","NSC-708298","Silatecan"],"crossReferences":{"PubChem":["582483"],"drugbank":["DB12384"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL414157","canonicalSmiles":"CCCn1c(=O)c2nc(C34CCC(CCC(=O)O)(CC3)CC4)[nH]c2n(CCC)c1=O","inchiKey":"ZWTVVWUOTJRXKM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TONAPOFYLLINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BG-9928","BG9928","Tonapofylline"],"crossReferences":{"drugbank":["DB12569"]},"childChemblIds":["CHEMBL535165"],"linkedTargets":{"rows":["ENSG00000163485"],"count":1},"linkedDiseases":{"rows":["HP_0000083","EFO_0003144","EFO_0001421","EFO_0000373"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL414883","canonicalSmiles":"C[C@@H]1C[C@H]2O[C@@H]2/C=C\\C=C\\C(=O)Cc2c(Cl)c(O)cc(O)c2C(=O)O1","inchiKey":"WYZWZEOGROVVHK-GTMNPGAYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RADICICOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Monorden","Radicicol"],"crossReferences":{"drugbank":["DB03758"],"chEBI":["556075"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297517","canonicalSmiles":"CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O","inchiKey":"RLCLASQCAPXVLM-NSHDSACASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MAVACAMTEN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mavacamten"],"crossReferences":{"drugbank":["DB14921"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297629","canonicalSmiles":"COc1ccc([C@@H](O)c2cc(-c3ncnc4cc(N5CCOCC5)ccc34)c(F)cc2Cl)nn1","inchiKey":"MOWXJLUYGFNTAL-DEOSSOPVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NEDISERTIB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["M-3814","M3814","MSC 2490484A","MSC-2490484A","MSC2490484A","Msc2490484a","Nedisertib","Peposertib"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL4297679","drugType":"Unknown","blackBoxWarning":false,"name":"10-1074","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["10-1074"],"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297870","drugType":"Antibody","blackBoxWarning":false,"name":"MITAZALIMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ADC-1013","Adc-1013","JNJ-64457107","JNJ-7107","Jnj-64457107","Mitazalimab","Vanalimab"],"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297941","drugType":"Unknown","blackBoxWarning":false,"name":"DSTA-4637S","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anti-s. aureus tac","DSTA-4637S","DSTA4637S","Dsta-4637s","Dsta4637s","RG-7861","RG7861"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4298012","drugType":"Antibody","blackBoxWarning":false,"name":"TESIDOLUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LFG-316","LFG316","Lfg316","NOV-4","Tesidolumab"],"linkedTargets":{"rows":["ENSG00000106804"],"count":1},"linkedDiseases":{"rows":["EFO_0004683","EFO_1000986","EFO_0001365","MONDO_0019541","Orphanet_447"],"count":5},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4298044","drugType":"Unknown","blackBoxWarning":false,"name":"MINT-1526A","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MINT-1526A","MINT1526A","Mint 1526a","Mint-1526a","Mint1526a","RG-7594"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4300152","canonicalSmiles":"F[Ag]","inchiKey":"REYHXKZHIMGNSE-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"SILVER DIAMMINE FLUORIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL4297206"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL436947","canonicalSmiles":"C#CCN(C)[C@@H]1CCc2ccccc21","inchiKey":"CSVGVHNFFZWQJU-CYBMUJFWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL436947","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02211"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL44","canonicalSmiles":"O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12","inchiKey":"TZBJGXHYKVUXJN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GENISTEIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Bonistein"],"synonyms":["(-)-.alpha.-isosparteine",".alpha.-isospartein",".alpha.-isosparteine",".alpha.-isosparteine, (-)-",".alpha.-sparteine","11-isosparteine","4',5,7-trihydroxyisoflavone","BIO 300","BIO-300","FW-635I-2","Genistein","Genisteine-alkaloid","Isosparteine, alpha-","NPI-031L","NSC-36586","NSC-366737","SIPI-807-1","Sophoricol","Sparteine l-.alpha.-isosparteine"],"crossReferences":{"PubChem":["104171167","11111233","11111234","11113921","124880228","124880229","144203712","144208626","144210902","162108258","170466848","17389520","26665855","26747156","26752075","26752076","50104732","50104733","50114251","50114252","85231066","90340706","93197"],"Wikipedia":["Genistein"],"drugbank":["DB01645"],"chEBI":["28088"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 16 investigational indications."}
{"id":"CHEMBL452596","canonicalSmiles":"O=C(O)c1cccc2c3c(n(Cc4ccccc4)c12)CCCC3","inchiKey":"VDOXYKGIKBUISK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL452596","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07283"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4594285","drugType":"Small molecule","blackBoxWarning":false,"name":"PADELIPORFIN POTASSIUM","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Padeliporfin (potassium)","Padeliporfin di-potassium","Padeliporfin dipotassium","Padeliporfin potassium","Stakel","WST-11 DIPOTASSIUM","WST11 DIPOTASSIUM","WST11 POTASSIUM"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4594419","canonicalSmiles":"CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O","inchiKey":"CMVHFGNTABZQJU-HCXYKTFWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BMS-813160","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-813160","Bms 813160","Bms-813160"],"linkedTargets":{"rows":["ENSG00000160791","ENSG00000121807"],"count":2},"linkedDiseases":{"rows":["EFO_0000401","EFO_0002517","EFO_0000536","EFO_0000311"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4650275","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"LUMASIRAN SODIUM","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Oxlumo"],"synonyms":["Lumasiran sodium"],"linkedTargets":{"rows":["ENSG00000101323"],"count":1},"linkedDiseases":{"rows":["Orphanet_93598"],"count":1},"description":"Oligonucleotide drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for primary hyperoxaluria type 1."}
{"id":"CHEMBL4650296","drugType":"Unknown","blackBoxWarning":false,"name":"BOS-589","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BOS-589","Bos-589","GSK3352589","Gsk3352589"],"linkedTargets":{"rows":["ENSG00000165731"],"count":1},"linkedDiseases":{"rows":["EFO_0000555"],"count":1},"description":"Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4650493","drugType":"Cell","blackBoxWarning":false,"name":"ZEDENOLEUCEL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MT-401","Mt-401","Zedenoleucel","Zelenoleucel"],"description":"Cell drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL473","canonicalSmiles":"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1","inchiKey":"IXTMWRCNAAVVAI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"DOFETILIDE","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dofetilide","Tikosyn"],"synonyms":["Dofetilide","UK-68,798","UK-68798"],"crossReferences":{"DailyMed":["dofetilide"],"PubChem":["144205731","170465418","26757968"],"Wikipedia":["Dofetilide"],"drugbank":["DB00204"],"chEBI":["4681"]},"linkedTargets":{"rows":["ENSG00000055118"],"count":1},"linkedDiseases":{"rows":["EFO_0000275","EFO_0004269","EFO_0003144","HP_0004308","HP_0001657"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4802215","drugType":"Antibody","blackBoxWarning":false,"name":"GALEGENIMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FHTR2163","Galegenimab","RG 6147","RG-6147","RO-7171009","RO7171009","Ro7171009"],"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL483995","canonicalSmiles":"CCOc1cccc(-c2ccc(NC(=O)/C(C#N)=C(/C)O)cc2)c1","inchiKey":"RPILZQUCBKIPAZ-AQTBWJFISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL483995","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07561"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL490730","canonicalSmiles":"CCCNC(=O)[C@@H]1CCCN1C(=O)[C@H](N)C(c1ccccc1)c1ccccc1","inchiKey":"HZKKJPDVZGOOPU-PZJWPPBQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL490730","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07083"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL509730","canonicalSmiles":"CC(C)Nc1cc(N[C@H]2CC[C@H](N)CC2)nc2c(C#N)cnn12","inchiKey":"FOESVLPZMGVWBM-JOCQHMNTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL509730","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08140"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL521703","canonicalSmiles":"CC1(C)CC[C@@]2(CC[C@H]3[C@@H]4CCc5cc(C(N)=O)ccc5[C@H]4CC[C@@]32C)OC1=O","inchiKey":"YVAJWBACBRSVPR-NDUHRLLKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL521703","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07700"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL522806","canonicalSmiles":"CC1=C(C(=O)c2ccccc2)[C@@H](c2cccc(O)c2)NC(=S)N1C","inchiKey":"JGBBILLMZPWNFU-QGZVFWFLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"(R)-MON-97","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08198"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL562314","canonicalSmiles":"NC[C@H]1CN(c2c(-c3ccccc3)cnc3[nH]ncc23)CCO1","inchiKey":"YBRZCAKSBYWZTC-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL562314","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08774"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL582","canonicalSmiles":"CC(C)O","inchiKey":"KFZMGEQAYNKOFK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ISOPROPYL ALCOHOL","yearOfFirstApproval":2000,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Manugel","Medi-swab","Medi-swab h","Sterets","Sterets h","Swim-ear","Zuragard"],"synonyms":["2-Propanol","2-propanol","2-propanolum","Alcohol,isopropyl","FEMA NO. 2929","IPA","Isopropanol","Isopropyl Alcohol","Isopropyl alcohol","NSC-135801"],"crossReferences":{"DailyMed":["isopropyl%20alcohol"],"PubChem":["144204590","144209673","17389846"],"Wikipedia":["Isopropyl_alcohol"],"drugbank":["DB02325"],"chEBI":["17824"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 13 approved and 2 investigational indications."}
{"id":"CHEMBL592374","canonicalSmiles":"Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl","inchiKey":"BSMNRYCSBFHEMQ-KCJUWKMLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMITIFADINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Amitifadine","DOV 21947","DOV-21,947","DOV-21947","EB1010"],"crossReferences":{"Wikipedia":["Amitifadine"],"drugbank":["DB05964"]},"childChemblIds":["CHEMBL1818442"],"linkedTargets":{"rows":["ENSG00000108576","ENSG00000103546","ENSG00000142319"],"count":3},"linkedDiseases":{"rows":["MONDO_0002009"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL595","canonicalSmiles":"CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1","inchiKey":"HYAFETHFCAUJAY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PIOGLITAZONE","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["AD-4833","Actos","Duetact","Glustin","Pioglitazone","U-72107","Zactos"],"crossReferences":{"DailyMed":["pioglitazone%20hydrochloride"],"PubChem":["137275816","174007207","26756476"],"Wikipedia":["Pioglitazone"],"drugbank":["DB01132"],"chEBI":["8228"]},"childChemblIds":["CHEMBL1715"],"linkedTargets":{"rows":["ENSG00000132170"],"count":1},"linkedDiseases":{"rows":["HP_0001397","EFO_0001361","HP_0002745","EFO_0003095","MONDO_0002009","EFO_0000756","EFO_0005669","EFO_0003914","HP_0100543","EFO_0000339","EFO_0002690","EFO_0000544","EFO_0004253","MONDO_0008903","EFO_0003884","EFO_0000676","EFO_1001348","MONDO_0004976","Orphanet_2495","EFO_0000400","Orphanet_379","EFO_0002618","EFO_0003756","EFO_0008620","Orphanet_100","HP_0003124","MONDO_0002108","EFO_0000384","EFO_0000660","MONDO_0008315","Orphanet_95","MP_0001845","MONDO_0004979","EFO_0001378","EFO_1001249","Orphanet_586","EFO_1000948","EFO_0000708","Orphanet_139399","EFO_0003085","MONDO_0005180","EFO_0000712","MONDO_0001657","EFO_0000673","EFO_0004272","EFO_0002499","EFO_0003047","MONDO_0007079","EFO_0000707","EFO_0002546","MONDO_0001437","HP_0012115","EFO_0000616","EFO_0000685","EFO_0001645","EFO_0000222","EFO_0003929","EFO_0000319","EFO_0010445","EFO_0001073","EFO_0000613","EFO_0003060","EFO_0000537","EFO_0000195","EFO_0000589","EFO_0004220","MONDO_0005301","MONDO_0005147","EFO_0001421","MONDO_0004975","EFO_0005611","MONDO_0005148","EFO_0000519","EFO_0004265"],"count":74},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 72 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL607712","canonicalSmiles":"O=C(O)C(=O)Cc1ccc(O)cc1","inchiKey":"KKADPXVIOXHVKN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4-HYDROXYPHENYLPYRUVIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-Hydroxy-Phenylpyruvate","4-Hydroxyphenylpyruvate"],"crossReferences":{"Wikipedia":["4-Hydroxyphenylpyruvic_acid"],"drugbank":["DB07718"],"chEBI":["15999"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL712","canonicalSmiles":"COc1ccc(C2C(=O)c3ccccc3C2=O)cc1","inchiKey":"XRCFXMGQEVUZFC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANISINDIONE","yearOfFirstApproval":1957,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Miradon"],"synonyms":["Anisindione","NSC-759629"],"crossReferences":{"PubChem":["144204923","14729672","170465379","26748631","50086377"],"Wikipedia":["Anisindione"],"drugbank":["DB01125"],"chEBI":["133809"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957."}
{"id":"CHEMBL808","canonicalSmiles":"Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1","inchiKey":"LEZWWPYKPKIXLL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ECONAZOLE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Econazole","NSC-187789","Spectazole"],"crossReferences":{"DailyMed":["econazole%20nitrate"],"PubChem":["104171384","448079"],"Wikipedia":["Econazole"],"drugbank":["DB01127"],"chEBI":["82873"]},"childChemblIds":["CHEMBL1201049"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for tinea pedis and has 1 investigational indication."}
{"id":"CHEMBL8145","canonicalSmiles":"O=c1c(-c2ccc(O)cc2)coc2cc(O)ccc12","inchiKey":"ZQSIJRDFPHDXIC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DAIDZEIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4',7-dihydroxyisoflavone","Daidzein"],"crossReferences":{"PubChem":["11111095","11114077","124879927","124879929","124879930","124879932","124879933","144208642","144213952","17389519","174007201","26747166","26747167","26752188","26752189","46500432","50085965","50104845","50104846","50104847","50113497","50113498","50126369","85231010","90341229"],"Wikipedia":["Daidzein"],"drugbank":["DB13182"],"chEBI":["28197"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL856","canonicalSmiles":"CCC1(c2ccccc2)C(=O)NCNC1=O","inchiKey":"DQMZLTXERSFNPB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PRIMIDONE","yearOfFirstApproval":1954,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Lepsiral","Liskantin","Mysoline","Neurosyn","Primidone"],"synonyms":["Lepimidin","NSC-41701","Primaclone","Primidone","Resimatil"],"crossReferences":{"DailyMed":["primidone"],"PubChem":["104171217","11111659","11112270","11113350","144203789","144209146","144213511","170464846","17389534","50104129","50126364","56324597","855864","90340844"],"Wikipedia":["Primidone"],"drugbank":["DB00794"],"chEBI":["8412"]},"linkedTargets":{"rows":["ENSG00000153253","ENSG00000185313","ENSG00000136531","ENSG00000183873","ENSG00000136546","ENSG00000196876","ENSG00000144285","ENSG00000169432","ENSG00000145864","ENSG00000168356","ENSG00000007314","ENSG00000166206","ENSG00000163288"],"count":13},"linkedDiseases":{"rows":["EFO_0000474","EFO_0000712"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for epilepsy and has 1 investigational indication."}
{"id":"CHEMBL87277","canonicalSmiles":"Cn1nc(C(C)(C)C)cc1NC(=O)Nc1ccc(Cl)cc1","inchiKey":"FWIJKWMXNHRSRO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL87277","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["26726546"],"drugbank":["DB02277"],"chEBI":["47249"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
